Peter Wilker

Assistant Professor
Year hired: Fall 2012

 

Education:

Saint Olaf College, 1996.  B.A. Biology
University of Minnesota-Twin Cities, 2002.  M.P.H. Epidemiology
Washington University in Saint Louis, 2008.  Ph.D. Immunology
University of Wisconsin-Madison, 2008-2012. Postdoctoral Fellow

Courses taught:

Immunology Laboratory (Mic 406/506)
Fundamentals of Microbiology Laboratory (Mic 230)

Research Interests:

Immunology of influenza viruses
Animal models of influenza
Viral adaptation and transmission dynamics

Hobbies/Interests

Spending time with my family, watching football, grilling meat and the occasional vegetable, avoiding yard work

Recent Publications:

Smith, K.E., Wilker, P.R., Reiter, P., Hedican, E.B., Bender, J.B., and Hedberg, C.W.  (2012). Antibiotic Treatment of Escherichia coli O157 Infection and the Risk of the Hemolytic Uremic Syndrome, Minnesota.   Pediatr Infect Dis J 31, 37-41.

Walsh, K.B., Teijaro, J.R., Wilker, P.R., Jatzek, A., Fremgen, D.M., Das, S.C., Watanabe, T., Hatta, M., Shinya, K., Suresh, M., et al. (2011). Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci USA 108, 12018-12023.

Kohyama, M., Ise, W., Edelson, B.T., Wilker, P.R., Hildner, K., Mejia, C., Frazier, W.A., Murphy, T.L., and Murphy, K.M. (2009). Role for Spi-C in the development of red pulp macrophages and splenic iron homeostasis. Nature 457, 318-321.

Wilker, P.R., Kohyama, M., Sandau, M.M., Albring, J.C., Nakagawa, O., Schwarz, J.J., and Murphy, K.M. (2008). Transcription factor Mef2c is required for B cell proliferation and survival after antigen receptor stimulation. Nat Immunol 9, 603-612.

Wilker, P.R., Sedy, J.R., Grigura, V., Murphy, T.L., and Murphy, K.M. (2007). Evidence for carbohydrate recognition and homotypic and heterotypic binding by the TIM family. Int Immunol 19, 763-773.
Bougie, D.W., Wilker, P.R., and Aster, R.H. (2006). Patients with quinine-induced immune thrombocytopenia have both "drug-dependent" and "drug-specific" antibodies. Blood 108, 922-927.

Bougie, D.W., Wilker, P.R., Wuitschick, E.D., Curtis, B.R., Malik, M., Levine, S., Lind, R.N., Pereira, J., and Aster, R.H. (2002). Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 100, 2071-2076.

Cunha, P.D., Lord, R.S., Johnson, S.T., Wilker, P.R., Aster, R.H., and Bougie, D.W. (2000). Immune hemolytic anemia caused by sensitivity to a metabolite of etodolac, a nonsteroidal anti-inflammatory drug. Transfusion 40, 663-668.